Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Johnson Chemical Pharmaceutical Works Co (ROCO:4747) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Johnson Chemical Pharmaceutical Works Co EBITDA Margin % Related Terms
Johnson Chemical Pharmaceutical Works Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson Chemical Pharmaceutical Works Co EBITDA Margin % Chart
Johnson Chemical Pharmaceutical Works Co Annual Data
ROCO:4747 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Johnson Chemical Pharmaceutical Works Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson Chemical Pharmaceutical Works Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson Chemical Pharmaceutical Works Co (ROCO:4747) has a EBITDA Margin % of -0.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors. Over the past decade, Johnson Chemical Pharmaceutical Works Co's EBITDA Margin % has ranged from 15.35 to 22.01. According to the industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #412 out of 961 companies in the Drug Manufacturers industry, placing it in the top 42.9%.
Is Johnson Chemical Pharmaceutical Works Co's EBITDA Margin % too high?
Johnson Chemical Pharmaceutical Works Co's current EBITDA Margin % is -0.56%. Over the past 10 years, this metric has ranged from a low of 15.35 to a high of 22.01. Based on the distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #412 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Johnson Chemical Pharmaceutical Works Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Johnson Chemical Pharmaceutical Works Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #412 out of 961 companies for EBITDA Margin %. This puts Johnson Chemical Pharmaceutical Works Co in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Historically, Johnson Chemical Pharmaceutical Works Co's own EBITDA Margin % has ranged from 15.35 to 22.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Johnson Chemical Pharmaceutical Works Co's current EBITDA Margin % is -0.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson Chemical Pharmaceutical Works Co stock overvalued right now?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co (ROCO:4747) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$60.21, compared to a current price of NT$49.95 — trading 17% below its estimated fair value. The current EBITDA Margin % is -0.56%. Johnson Chemical Pharmaceutical Works Co's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Johnson Chemical Pharmaceutical Works Co (ROCO:4747), the current EBITDA Margin % is -0.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson Chemical Pharmaceutical Works Co (ROCO:4747) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co stock appears to be undervalued.
The current stock price of NT$49.95 is trading 17% below its estimated GF Value™ of NT$60.21.
GuruFocus considers Johnson Chemical Pharmaceutical Works Co to be Modestly Undervalued.
Key valuation signals for ROCO:4747:
EBITDA Margin %: -0.56%
GF Value™: NT$60.21 vs. price of NT$49.95 (17% below fair value)
No single metric tells the full story. See the ROCO:4747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson Chemical Pharmaceutical Works Co Business Description
Johnson Chemical Pharmaceutical Works Co is engaged in the manufacturing of pharmaceutical ingredients, importing and selling pharmaceutical materials and products. It manufactures drugs in a variety of forms, including solid dosage forms, capsules (soft/hard), tablets (sugar/film-coated), powder and granule, as well as nasal sprays. It offers products in therapeutic areas including the central nervous system, respiratory, cardiovascular, gastrointestinal, and endocrine system, vitamins, anti-inflammatory, cough and cold, and pain relievers. Its revenue mainly comes from medical product sales.
77GF Score
Get the complete analysis for ROCO:4747
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4747 has been successfully added to your 
